The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: A review

Current Opinion in Infectious Diseases

Volumn 26, Issue 5, 2013, Pages 420-428

  Epstein, Judith E ^a   Richie, Thomas L ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

genetically attenuated; malaria; radiation attenuated; review; sporozoite; vaccines; whole organism

Indexed keywords

AZITHROMYCIN; CHLOROQUINE; CLINDAMYCIN; DNA; GAMMA INTERFERON; MALARIA VACCINE; MEFLOQUINE; NITRIC OXIDE; PRIMAQUINE; PYRIMETHAMINE; SPOROZOITE VACCINE;

ANOPHELES; ANTIBODY RESPONSE; ANTIMALARIAL ACTIVITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IRRADIATION; LEUKAPHERESIS; LIFE CYCLE; LIVER CELL; LYMPHOCYTE SUBPOPULATION; MALARIA; MALARIA FALCIPARUM; NONHUMAN; PARASITE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM BERGHEI; PLASMODIUM VIVAX MALARIA; PLASMODIUM YOELII; RADIATION; REVIEW; SPOROZOITE;

ANIMALS; HUMANS; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; SPOROZOITES; VACCINES, ATTENUATED;

EID: 84883600823     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000002     Document Type: Review

References (81)

1. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-1875.
2. Agnandji S, Lell B, Fernandes J, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-2295.
3. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111-1120.
4. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-1164.
5. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-477.
6. Roestenberg M, Teirlinck AC, McCall MB, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377:1770-1776.
7. Hoffman SL, Billingsley P, James E, et al. Development of a metabolically active, nonreplicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010; 6:97-106.
8. Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8\+T cell immunity. Science 2011; 334:475-480.
9. Butler NS, Vaughan AM, Harty JT, Kappe SH. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol 2012; 33:247-254.
10. Mulligan HW, Russell P, Mohan BN. Active immunization of fowls against Plasmodium gallinaceum by injections of killed homologous sporozoites. Journal of the Malaria Institute of India 1941; 4:25-34.
11. Richards WGH. Active immunization of chicks against Plasmodium gallinacium by inactivated homologous sporozoites and erythrocytic parasites. Nature 1966; 212:1492-1494.
12. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967; 216:160-162.
13. Beaudoin RL, Strome CPA, Mitchell F, Tubergen TA. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977; 42:1-5.
14. Belnoue E, Costa FTM, Frankenberg T, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004; 172:2487-2495.
15. Mueller AK, Camargo N, Kaiser K, et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 2005; 102:3022-3027.
16. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005; 433:164-167.
17. van Dijk MR, Douradinha B, Franke-Fayard B, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 2005; 102:12194-12199.
18. Orjih AU, Cochrane AH, Nussenzweig RS. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. Trans R Soc Trop Med Hyg 1982; 76:57-61.
19. Purcell LA, Wong KA, Yanow SK, et al. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and crossprotection against heterologous challenge. Vaccine 2008; 26:4880-4884.
20. Purcell LA, Yanow SK, Lee M, et al. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun 2008; 76:1193-1199.
21. Luke TC, Hoffman SL. Rationale and plans for developing a nonreplicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003; 206:3803-3808.
22. Alger NE, Harant J. Plasmosium berghei: heat-treated sporozoite vaccination of mice. Exp Parasitol 1976; 40:261-268.
23. Schofield L, Villaquiran J, Ferreira A, et al. Gamma-interferon, CD8\+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330:664-666.
24. Weiss WR, Sedegah M, Beaudoin RL, et al. CD8\+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 1988; 85:573-576.
25. Doolan DL, Hoffman SL. IL-12 and NK cells are required for antigenspecific adaptive immunity against malaria initiated by CD8\+ T cells in the Plasmodium yoelii model. J Immunol 1999; 163:884-892.
26. Doolan DL, Hoffman SL. The complexity of protective immunity against liverstage malaria. J Immunol 2000; 165:1453-1462.
27. Trimnell A, Takagi A, Gupta M, et al. Genetically attenuated parasite vaccines induce contact-dependent CD8\+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol 2009; 183:5870-5878.
28. Krzych U, Dalai S, Zarling S, Pichugin A. Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol 2012; 3:370.
29. Weiss WR, Jiang CG. Protective CD8\+T lymphocytes in primates immunized with malaria sporozoites. PLoS One 2012; 7:e31247.
30. Malik A, Egan JE, Houghten RA, et al. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 1991; 88:3300-3304.
31. Wizel B, Houghten RA, Parker KC, et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med 1995; 182:1435-1445.
32. Doolan DL, Hoffman SL, Southwood S, et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 1997; 7:97-112.
33. Doolan DL, Southwood S, Freilich DA, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci USA 2003; 100:9952-9957.
34. Nganou-Makamdop K, van Gemert GJ, Arens T, et al. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFN responses of hepatic CD8\+ memory T cells. PLoS One 2012; 7:e36508.
35. Zarling S, Berenzon D, Dalai S, et al. The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria. J Immunol 2013; 190:5128-5141.
36. Teirlinck AC, McCall MB, Roestenberg M, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog 2011; 7:e1002389.
37. Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995; 92:4066-4068.
38. Renia L, Gruner AC, Mauduit M, Snounou G. Vaccination using normal live sporozoites under drug treatment. Methods Mol Biol 2013; 923:567-576.
39. Vaughan AM, Kappe SH. Vaccination using radiation: or genetically attenuated live sporozoites. Methods Mol Biol 2013; 923:549-566.
40. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013; [Epub ahead of print]. The authors have demonstrated in a small group of human volunteers that IV administration of the PfSPZ vaccine (attenuated, aseptic, purified, cryopreserved PfSPZ) is safe and well tolerated and results in 100% protective efficacy against controlled human malaria infection.
41. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266:169-177.
42. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266:398-403.
43. Clyde DF, McCarthy VC, Miller RM, Woodward WE. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975; 24:397-401.
44. Clyde DF. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-1975. Bull World Health Organ 1990; 68 (Suppl):9-12.
45. Rieckmann KH, Carson PE, Beaudoin RL, et al. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974; 68:258-259.
46. Rieckmann KH, Beaudoin RL, Cassells JS, Sell DW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 1979; 57 (Suppl):261-265.
47. Rieckmann KH. Human immunization with attenuated sporozoites. Bull World Health Organ 1990; 68 (Suppl):13-16.
48. McCarthy VC, Clyde DF. Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol 1977; 41:167-171.
49. Herrington D, Davis J, Nardin E, et al. Successful immunization of humans with irradiated sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991; 45:539-547.
50. Edelman R, Hoffman SL, Davis JR, et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 1993; 168:1066-1070.
51. Egan JE, Hoffman SL, Haynes JD, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993; 49:166-173.
52. Rostenberg M, Bijker EM, Aim BK, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium faliciparum sporozoites. Am J Trop Med Hyg 2013; 88:5-13.
53. Epstein JE. Taking a bite out of malaria: controlled human malaria infection by needle and syringe. Am J Trop Med Hyg 2013; 88:3-4.
54. Sheehy SH, Spencer AJ, Douglas AD, et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One 2013; 8:e65960.
55. Nganou-Makamdop K, Ploemen I, Behet M, et al. Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Parasite Immunol 2012; 34:562-569.
56. Ploemen IH, Chakravarty S, van Gemert GJ, et al. Plasmodium liver load following parenteral sporozoite administration in rodents. Vaccine 2012; 31:3410-3416.
57. Wijayalath W, Cheesman S, Tanabe K, et al. Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover. PLoS One 2012; 7:e45861.
58. Schmidt NW, Butler NS, Badovinac VP, Harty JT. Extreme CD8 T cell requirements for antimalarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 2010; 6:e1000998.
59. Murphy SC, Kas A, Stone BC, Bevan MJ. A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations. Proc Natl Acad Sci USA 2013; 110:6055-6060.
60. Golenser J, Heeren J, Verhave JP, et al. Crossreactivity with sporozoites, exoerythrocytic forms and blood schizonts of Plasmodium berghei in indirect fluorescent antibody tests with sera of rats immunized with sporozoites or infected blood. Clin Exp Immunol 1977; 29:43-51.
61. Bijker EM, Bastiaens GJ, Teirlinck AC, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 2013; 110:7862-7867.
62. Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003; 197:143-151.
63. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7:165-172.
64. Sauerwein RW, Bijker EM, Richie TL. Empowering malaria vaccination by drug administration. Curr Opin Immunol 2010; 22:367-373.
65. Friesen J, Matuschewski K. Comparative efficacy of preerythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011; 29:7002-7008.
66. Khan SM, Janse CJ, Kappe SH, Mikolajczak SA. Genetic engineering of attenuated malaria parasites for vaccination. Curr Opin Biotechnol 2012; 23:908-916.
67. Labaied M, Harupa A, Dumpit RF, et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007; 75:3758-3768.
68. van Schaijk BC, Janse CJ, van Gemert GJ, et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PloS One 2008; 3:e3549.
69. Yu M, Kumar TR, Nkrumah LJ, et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 2008; 4:567-578.
70. Vaughan AM, O'Neill MT, Tarun AS, et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 2009; 11:506-520.
71. Ishino T, Boisson B, Orito Y, et al. LISP1 is important for the egress of Plasmodium berghei parasites from liver cells. Cell Microbiol 2009; 11:1329-1339.
72. Pei Y, Tarun AS, Vaughan AM, et al. Plasmodium pyruvate dehydrogenase activity is only essential for the parasite's progression from liver infection to blood infection. Mol Microbiol 2010; 75:957-971.
73. Butler NS, Schmidt NW, Vaughan AM, et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011; 9:451-462.
74. Mikolajczak SA, Sacci JB Jr, De La Vega P, et al. Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites. Cell Microbiol 2011; 13:1250-1260.
75. Falkard B, Kumar TR, Hecht LS, et al. A key role for lipoic acid synthesis during Plasmodium liver stage development. Cell Microbiol 2013; 15:1585-1604.
76. Falae A, Combe A, Amaladoss A, et al. Role of Plasmodium berghei cGMPdependent protein kinase in late liver stage development. J Biol Chem 2010; 285:3282-3288.
77. Annoura T, Ploemen IH, van Schaijk BC, et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012; 30:2662-2670.
78. Nagel A, Prado M, Heitmann A, et al. A new approach to generate a safe double-attenuated Plasmodium liver stage vaccine. Int J Parasitol 2013; 43:503-514.
79. van Schaijk BC, Vos MW, Janse CJ, et al. Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase. PloS One 2010; 5:e15121.
80. O'Neill MT, Phuong T, Healer J, et al. Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied sitespecific recombination. Int J Parasitol 2011; 41:117-123.
81. Nganou-Makamdop K, Sauerwein RW. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better? Trends Parasitol 2013; 29:304-310.